Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2019 16:05 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update

Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2 summit Company to host...
May 06, 2019 16:58 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Announce First Quarter 2019 Results on May 13th

SAN DIEGO, May 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
April 16, 2019 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology

SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
April 11, 2019 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund

SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
April 08, 2019 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference

SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
March 25, 2019 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update

Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018 First tRNA synthetase partnership announced in March 2019 SAN DIEGO,...
March 21, 2019 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
March 18, 2019 16:46 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th

SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
March 11, 2019 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring

Partnership to accelerate development of IND candidates from tRNA synthetases in aTyr’s pipeline aTyr eligible to receive up to $17 million in potential option fees SAN DIEGO, March 11, 2019 ...
March 04, 2019 17:36 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Participation at March Investor Conferences

SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...